XenoPort Ends Study of Back Spasm Drug Candidate
Tue, 09/08/2009 - 4:37am
SANTA CLARA, Calif. (AP) — Biotechnology firm XenoPort Inc. said Tuesday it will stop developing its compound XP19986 as a potential back spasm treatment because of "high variability" in the drug candidate's effectiveness during a midstage study. The goal of the Phase II clinical trial was safety, which arbaclofen placarbil or XP19986 met. But, there was no difference in effectiveness when compared with patients taking placebo. The company will continue developing the drug candidate as a potential treatment for acid reflux disease and spasticity, which is a nervous system disorder affecting the muscles.